Provides a concise summary of the latest AHA/ACC guidelines for managing cardiovascular medications during the perioperative period of noncardiac surgery.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Captured external expert commentary on this paper, strongest first. Original sources are linked where available.
“There is a wealth of new evidence about how best to evaluate and manage perioperative cardiovascular risk in patients undergoing noncardiac surgery. Worldwide, there are approximately 300 million noncardiac surgeries each year, which underscores the need to summarize and interpret the evidence to assist clinicians in managing patients who present for surgery. This new guideline is a comprehensive review of the latest research to help inform clinicians who manage perioperative patients, with the ultimate goal of restoring health and minimizing cardiovascular complications.”
“Our role in this process is not to 'clear' patients for surgery, but to estimate the risks and benefits of surgery, guide medical decisions, and facilitate informed decision making between the surgeons, anesthesiologists, and—most importantly—the patient.”
Clinicians should apply updated perioperative CV medication adjustments to reduce risks; extends prior guidelines with new evidence.
This JAMA Clinical Guidelines Synopsis summarizes the 2024 recommendations from the American Heart Association and American College of Cardiology on perioperative cardiovascular medication management for noncardiac surgery.
Winchester et al. (2026) studied this question. The 2024 AHA/ACC clinical guidelines provide updated recommendations for perioperative cardiovascular medication management in patients undergoing noncardiac surgery.
Synapse has enriched 10 related papers. Consider them for comparative context: